| abstract |
The present invention relates to a novel class of agents that target the androgen receptor (ARTA), which contains a part of haloacetamide or azide and are alkylating agents. These agents that define a new subclass of compounds, namely selective androgen receptor modulators (SARMs) which, either alone, or in a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example, conditions associated with the Androgen Decline in Elderly Men (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadym, osteoporosis , hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis benign prostatic hyperplasia, alterations in mood and knowledge and prostate cancer; c) treatment of conditions associated with the Androgen Decline in Women (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in knowledge and mood, depression, anemia, hair loss, obesity , endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of conditions of acute and / or chronic muscle wasting; e) prevention and / or treatment of dry eye conditions; f) oral androgen replacement therapy; g) decrease in the incidence of, interruption or regression origin of prostate cancer; and / or h) induction of apoptosis in a cancer cell. |